From The Editor

  1. Cell Therapy Manufacturing Trends And Advancements Continuing In 2025 12/26/2024

    In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.

  2. Exciting Areas Of Innovation For Cell Therapies 12/23/2024

    In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.

  3. ADCs: Leading With The Linker 12/20/2024

    Leo Marx, Ph.D., the Medicinal Chemistry Project and Bioconjugation Manager at Debiopharm, shares his company's rationale for the company's ADC development decisions and why its linker technology is the tip of the spear for those that make the cut.

  4. Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific? 12/19/2024

    Antibodies are the biotherapeutic bulwark, the steadfast stalwart in not just oncology, but infectious and chronic inflammatory diseases as well. We consulted with a variety of antibody developers for insight into the challenges and opportunities antibody modalities face in the coming year and beyond.

  5. Leveraging Directed Evolution To Optimize AAV Vector Design 12/18/2024

    4D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.

  6. Inside Interius' Global Regulatory Strategy 12/13/2024

    Interius BioTherapeutics' lentiviral gene therapy INT2104, which creates CAR T and CAR NK cells in vivo, headed to clinical trials in Australia where the company dosed a first patient with a B-cell malignancy. CEO Phil Johnson, M.D. gave us a look inside the company's global regulatory strategy.

  7. Internalizing Nanoparticle Therapeutic Development 12/3/2024

    De facto approaches to treating immune-mediated diseases aren’t very kind to the immune system itself. COUR Pharmaceuticals is leveraging nanoparticles, a purpose-built platform and in-house expression systems to build antigen-specific therapies that treat the root cause of autoimmune diseases.

  8. Coya Therapeutics On Developing A Combination Biologic 10/31/2024

    Coya Therapeutic’ executive chairman, Howard Berman, Ph.D., discusses the company's approach to developing a combination biologic and the challenges that multi-targeted therapeutics present.

  9. Inside J&J's Many-Indication mAb 10/30/2024

    Leona Ling, Ph.D.’s relationship with the investigational monoclonal antibody nipocalimab is defined by curiosity, perseverance, and commitment. She discovered the molecule while working for Momenta Pharmaceuticals, and she continues to shepherd it long after J&J's $6.5 billion bid for it in 2020.

  10. How Cidara Got Its Molecule Back 10/30/2024

    In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a deal with J&J, is now squarely back in the biotech's hands and moving forward with an aggressive phase 2b study.